Valuation: Alligator Bioscience AB

Market Cap 8.29M 837K 744K 690K 628K 1.18M 79.46M 1.2M 3.25M 41.46M 3.14M 3.08M 132M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 8.29M 837K 744K 690K 628K 1.18M 79.46M 1.2M 3.25M 41.46M 3.14M 3.08M 132M EV / Sales 2026 *
1.41x
EV / Sales 2027 * 0.17x
Free-Float
38.38%
Yield 2026 *
-
Yield 2027 * -
1 week-8.97%
Current month-34.00%
1 month-37.14%
3 months-93.04%
6 months-95.91%
Current year-96.08%
1 week 0.01
Extreme 0.0126
0.02
1 month 0.01
Extreme 0.0126
0.02
Current year 0.01
Extreme 0.0126
0.49
1 year 0.01
Extreme 0.0126
3.56
3 years 0.01
Extreme 0.0126
1,568
5 years 0.01
Extreme 0.0126
3,000
10 years 0.01
Extreme 0.0126
40,100
Manager TitleAgeSince
Chief Executive Officer 55 01/06/2021
Director of Finance/CFO 61 12/08/2024
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 01/06/2021
Director/Board Member 68 09/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
05/03/25 Buy

Chairman

800,000 0.0047%
05/03/25 Buy

Chairman

77,319 0.0005%
05/03/25 Sell

Chairman

1,658,134 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.97%-99.60%-100.00% 837K
-6.60%-8.56%+49.38%+64.90% 65B
-0.30%+4.84%+8.82%+75.96% 51.2B
+0.82%-0.11%+0.33%+62.47% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+6.53%+8.02%+16.40%+56.32% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-0.20%+0.16%+25.40%+25.43% 22.5B
Average -0.97%-1.69%+31.39%+83.19% 37.24B
Weighted average by Cap. -1.53%-0.50%+44.31%+104.99%

Financials

2026 *2027 *
Net sales 5.9M 596K 530K 491K 447K 843K 56.54M 856K 2.31M 29.51M 2.24M 2.19M 94.06M 49.7M 5.02M 4.46M 4.13M 3.76M 7.1M 476M 7.21M 19.49M 249M 18.83M 18.43M 792M
Net income -15.2M -1.53M -1.36M -1.26M -1.15M -2.17M -146M -2.21M -5.96M -76.01M -5.76M -5.64M -242M 28.9M 2.92M 2.59M 2.4M 2.19M 4.13M 277M 4.19M 11.33M 145M 10.95M 10.72M 461M
Net Debt - -
Projected Income Statement - Annual - Alligator Bioscience AB
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change Volume
19/10/26 SEK 0.0132 0.00% 506,807
16/10/26 SEK 0.0132 +1.54% 22,150,075
15/10/26 SEK 0.0130 -2.99% 12,509,086
14/10/26 SEK 0.0134 -8.84% 75,997,507
13/10/26 SEK 0.0147 +1.38% 92,601,964
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alligator Bioscience AB
  1. Stock Market
  2. Stocks
  3. ATORX Stock